Comparative Pharmacology
Head-to-head clinical analysis: TRIAMCINOLONE ACETONIDE versus UCERIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRIAMCINOLONE ACETONIDE versus UCERIS.
TRIAMCINOLONE ACETONIDE vs UCERIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to glucocorticoid receptors, leading to inhibition of phospholipase A2, decreased prostaglandin and leukotriene synthesis, and suppression of inflammatory cytokines.
Uceris (budesonide) is a corticosteroid with potent glucocorticoid activity. It binds to the glucocorticoid receptor, leading to inhibition of pro-inflammatory cytokines (e.g., IL-1, IL-2, IL-4, IL-5, TNF-alpha), suppression of arachidonic acid metabolism via phospholipase A2 inhibition, and reduction of inflammatory cell infiltration. It has high topical anti-inflammatory activity and undergoes extensive first-pass hepatic metabolism, minimizing systemic bioavailability.
Intramuscular: 40-80 mg every 4 weeks. Intra-articular: 5-40 mg depending on joint size. Topical: Apply thin film to affected area 2-4 times daily.
For induction of remission in mild to moderate active ulcerative colitis: one 9 mg extended-release tablet orally once daily for up to 8 weeks.
None Documented
None Documented
Terminal elimination half-life approximately 2-5 hours; but suppression of adrenal function (HPA axis) can persist for 7-30 days depending on dose and duration.
2.8-4.5 hours (terminal). Clinical context: short half-life supports once-daily extended-release formulation for colonic delivery.
Renal (primarily as metabolites, <5% unchanged); biliary/fecal (minor).
Renal: <1%. Fecal: approximately 63% as budesonide and metabolites. Biliary: minor.
Category D/X
Category C
Corticosteroid
Corticosteroid